Compare
Aldeyra Therapeutics, Inc. vs Corvus Pharmaceuticals, Inc. vs Inovio Pharmaceuticals, Inc. vs Werewolf Therapeutics, Inc.
| Latest fiscal year | Aldeyra Therapeutics, Inc. ALDX | Corvus Pharmaceuticals, Inc. CRVS | Inovio Pharmaceuticals, Inc. INO | Werewolf Therapeutics, Inc. HOWL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $65.3K | n/a |
| Revenue growth (YoY) | n/a | n/a | -70.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$33.85M | -$15.28M | -$84.95M | -$60.82M |
| EPS (Diluted) | -$0.56 | -$0.53 | -$1.81 | -$1.33 |
| Operating cash flow | -$33.35M | -$32.80M | -$88.63M | -$60.29M |
| Free cash flow | n/a | -$32.97M | -$88.92M | -$60.29M |
| Cash & equivalents | $70.04M | $4.58M | $44.27M | $57.05M |
| Total assets | $72.06M | $71.12M | $74.31M | $69.40M |
| Total liabilities | $27.81M | $9.91M | $50.21M | $44.59M |
| Shareholders' equity | $44.25M | $61.20M | $24.10M | $24.80M |
| Return on year-end equity | -76.5% | -25.0% | -352.5% | -245.2% |
| Shares outstanding | 60.16M | 74.70M | 69.00M | 48.60M |
Revenue, most recent five fiscal years
| Fiscal year | Aldeyra Therapeutics, Inc. | Corvus Pharmaceuticals, Inc. | Inovio Pharmaceuticals, Inc. | Werewolf Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $65.3K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $217.8K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $832.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $10.26M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $1.77M Ended 2021-12-31 | n/a |